ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0474

Association Between Rheumatoid Arthritis and Survival After Cancer: A Systematic Literature Review and Meta-analysis
Abstract Number: 0900

Association Between Serum Urate, Gout, and Prostatic Cancer in European Male Populations: A Mendelian Randomization Study
Abstract Number: 2221

Association Between Serum Uric Acid/Serum Creatinine Index and Carotid Plaque in Patients with Rheumatoid Arthritis
Abstract Number: 1998

Association Between Small Interfering RNA Therapy and Autoimmune Diseases: U.S. Prospective Cohort Study
Abstract Number: 2110

Association Between Symptomatic Knee Osteoarthritis and Blood Glucose Control in Persons with Type 2 Diabetes
Abstract Number: 0100

Association Between the Active Form of Plasminogen Activator Inhibitor 1 (PAI-1) and Endothelial Cell Activation in Antiphospholipid Syndrome
Abstract Number: 1512

Association Between the Systemic Immune Inflammatory Index (Sll) and All-cause Mortality in Critically Ill Patients with Rheumatoid Arthritis
Abstract Number: 1356

Association Between Vascular Inflammation and Kidney Function in Patients with Rheumatoid Arthritis: Secondary Analysis of TARGET Trial
Abstract Number: 0697

Association of ANCA-Associated Vasculitis and Development of SSc and SSc-Associated Antibodies: Impact of Pulmonary Arterial Hypertension
Abstract Number: 0488

Association of Anti-CarP Levels with Clinical Activity and Serological Profile in Rheumatoid Arthritis
Abstract Number: 2058

Association of Anti-Synthetase Antibody Subtypes with Radiographic Progression of Interstitial Lung Disease in Anti-Synthetase Syndrome: An Analysis of the CLASS Project Database
Abstract Number: 1429

Association of Bone Erosion and Microarchitecture with Disease Activity and Damage in Sjögren’s Disease
Abstract Number: 2219

Association of Chondrocalcinosis with Disease Activity and Drug Response in Rheumatoid Arthritis: Baseline Characteristics of the Swiss Rheumatoid Arthritis Outcomes Cohort
Abstract Number: 0122

Association of Cognitive Impairment Measured by Montreal Cognitive Assessment and Plasma Levels of Growth Differentiation Factor 15 in Patients with Antiphospholipid Antibody Syndrome
Abstract Number: 1433

Association of Contextual Factors with Sonographic Inflammatory and Structural Phenotypes in Psoriatic Arthritis Patients

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].